Investors
Oxurion/Investors/News/First Patient Dosed in Part B of Phase 2 KALAHARI Study E…

First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME)